Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

Figure 5

Western blot of nuclear hormone receptors and proliferation in A375(DRO) cells with shRXRg infection. A. – 60 μg of nuclear protein extract from A375(DRO), the SCR shRNA infected control cell and a clone of shRXRγ infected cells were size-separated on a 10% SDS-PAGE gel and transferred to nitrocellulose. The blot was blocked with 10% nonfat milk and incubated with RXRγ, RXRα and PPARγ primary antibodies and then secondary antibody with anti-rabbit IgG conjugated to horse-radish peroxidase as previously described. β-actin was measured as a loading control. B. – A375(DRO), the SCR infected and the shRXRγ infected sublines were grown in 2% fetal bovine serum RPMI in the presence of 1 umol/L of LGD1069, TZD or the combination for 9 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Proliferation was compared to that of cells grown in volume equivalent vehicle (DMSO – represented by the line). Proliferation of the SCR infected A375(DRO) was compared to the native cell line to confirm a similar response and then the shRXRγ infected cell line was compared to the SCR condition for an assessment of attenuation of decreased proliferation. Proliferation was statistically significantly attenuated compared to the A375(DRO) SCR subline in all treatment conditions (p < 0.05). Columns, mean; bars, SEM.

Back to article page